ReviewAnais brasileiros de dermatologia
Mycosis fungoides and Sézary syndrome: focus on the current treatment scenario.
Review in Anais brasileiros de dermatologia. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 19 citations in OpenAlex.
- Development of mogamulizumab-associated rash with granuloma annulare-like features in a patient with Sezary syndrome: A case report and review of the literature.JAAD case reports · 2026Article
- Delayed Diagnosis of Sézary Syndrome: Lessons From a Psoriasiform Presentation.Clinical case reports · 2026Article
- Early-Onset Hypopigmented Mycosis Fungoides in a Young Female: Navigating Diagnostic Delays and Treatment Complexities-A Case Report.Clinical case reports · 2025Article
- Review
- A Narrative Review of the State of the Art of CCR4-Based Therapies in Cutaneous T-Cell Lymphomas: Focus on Mogamulizumab and Future Treatments.Antibodies (Basel, Switzerland) · 2024Review
- Diagnostic Approach to Adult Erythroderma: A Rare Case of Sezary Syndrome.Iranian journal of pathology · 2024Article
- Dupilumab-associated mycosis fungoides: a cross-sectional study.Archives of dermatological research · 2023Article
- Article
- Trends in risk for therapy-related myelodysplastic syndrome/acute myeloid leukemia after initial chemo/immunotherapy for common and rare lymphoid neoplasms, 2000-2018.EClinicalMedicine · 2023Article
- Mycosis fungoides and Sézary syndrome: clinical presentation, diagnosis, staging, and therapeutic management.Frontiers in oncology · 2023Review
- Suggested Guidelines for the Treatment of Mycosis Fungoides in Countries with Limited Resources.Dermatology research and practice · 2023Review
- Dupilumab-Associated Sezary Syndrome.Indian journal of dermatologyArticle
- Educational Case: Mycosis fungoides.Academic pathologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cutaneous T-cell lymphomas are a heterogeneous group of lymphoproliferative disorders, characterized by infiltration of the skin by mature malignant T cells. Mycosis fungoides is the most common form of cutaneous T-cell lymphoma, accounting for more than 60% of cases. Mycosis fungoides in the early-stage is generally an indolent disease, progressing slowly from some patches or plaques to more widespread skin involvement. However, 20% to 25% of patients progress to advanced stages, with the development of skin tumors, extracutaneous spread and poor prognosis. Treatment modalities can be divided into two groups: skin-directed therapies and systemic therapies. Therapies targeting the skin include topical agents, phototherapy and radiotherapy. Systemic therapies include biological response modifiers, immunotherapies and chemotherapeutic agents. For early-stage mycosis fungoides, skin-directed therapies are preferred, to control the disease, improve symptoms and quality of life. When refractory or in advanced-stage disease, systemic treatment is necessary. In this article, the authors present a compilation of current treatment options for mycosis fungoides and Sézary syndrome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.